MAPK10 and Mental deterioration: Importantly, JNK3 was detected in the cerebrospinal fluid (CSF) of AD patients, and its increased level is statistically correlated with the rate of cognitive decline [123], indicating that JNK3 is a key player in this disease but probably can be also a biomarker in AD.